Overall survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy may leads to lower progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
It is very uncertain whether TG4010 added to chemotherapy changes participants with at least one serious adverse event compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Survival rates at 3 years · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in survival rates at 3 years compared with chemotherapy alone (low certainty).
1 finding from 1 review
Survival rates at 5 years · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival1 · Patients with advanced non‐small cell lung cancer
The intervention leads to lower overall survival1 (high certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival1 · Patients with advanced non‐small cell lung cancer
The intervention showed no clear difference in progression‐free survival1 (low certainty).
1 finding from 1 review
Intervention not reported
One‐year survival rate2 · Patients with advanced non‐small cell lung cancer
The intervention leads to higher one‐year survival rate2 (high certainty).
1 finding from 1 review
Intervention not reported
Objective response rate2 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher objective response rate2 (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life3 · Patients with advanced non‐small cell lung cancer
1 finding from 1 review
Intervention not reported
Serious adverse events2,4 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher serious adverse events2,4 (low certainty).
1 finding from 1 review
RR 37.36 [10.66, 130.95]
1 study · 4 participants
Low